This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Galapagos' CF Candidate Shows Potential in Phase II Study
by Zacks Equity Research
Galapagos' (GLPG) CFTR corrector candidate, GLPG2222, shows potential in a phase II study on CF patients.
Biotechs Trading Lower in Q4 on Macro Uncertainty, Tepid Q3
by Zacks Equity Research
After rising 15.4% in the first nine months of the year, the Medical-Biotech /Genetics industry has declined 13.4% so far in the fourth quarter.
Biotech Stock Roundup: Dynavax Vaccine Gets FDA Nod, Loxo Inks Deal with Bayer
by Arpita Dutt
Regulatory actions and licensing and collaboration agreements were the key highlights this week with companies like Loxo Oncology (LOXO) remaining in the limelight.
Vertex Gets CHMP Recommendation for Orkambi Label Expansion
by Zacks Equity Research
Vertex (VRTX) received CHMP recommendation for label expansion of Orkambi in children aged 6 to 11 years with CF who have two copies of the F508del mutation.
Biotech Stock Roundup: Regeneron Delivers Strong Q3 Results, Cellectis Clinical Hold Lifted
by Arpita Dutt
While focus remained on Regeneron's (REGN) Q3 earnings, Dicerna was also in the news related to its collaboration agreement with Boehringer Ingelheim.
Biotech Stock Roundup: Celgene, Amgen, Gilead Hit by Q3 Results, Vertex Beats on All Fronts
by Arpita Dutt
It was all about earnings this week with major biotech companies like Gilead (GILD), Celgene and Amgen reporting third quarter results.
Vertex (VRTX) Beats on Q3 Earnings & Sales, Raises 2017 View
by Zacks Equity Research
Vertex Pharma (VRTX) third-quarter earnings increased from the year-ago period led by strong sales of CF drugs.
Biotech Stock Roundup: Biogen Tops Q3 Earnings, Gilead's CAR T Drug Gets FDA Nod
by Arpita Dutt
Key highlights include Biogen's (BIIB) Q3 results and regulatory news from companies like Gilead and Alexion.
Drug/Biotech Stocks Q3 Earnings on Oct 25: AMGN, GSK, VRTX
by Zacks Equity Research
The pharma/biotech industry has seen a solid start to Q3 earnings as evident from J&J's encouraging results. Let's see if some of the other leading players - Amgen, Glaxo and Vertex - follow suit.
Why Earnings Season Could Be Great for Vertex Pharmaceuticals (VRTX)
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Is Celgene (CELG) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Celgene Corporation (CELG) is expected to beat estimates once again on the back of strong performance of key drug Revlimid.
Is Gilead (GILD) Poised for a Beat This Earnings Season?
by Zacks Equity Research
A leader in the hepatitis C virus (HCV) space, Gilead Sciences' (GILD), is expected to beat expectations when it reports third-quarter results on Oct 26, after the market closes.
Is a Beat in the Cards for Vertex (VRTX) in Q3 Earnings?
by Zacks Equity Research
Vertex's (VRTX) Kalydeco is expected to generate increased revenues following its label expansion in the third quarter of 2017.
4 of the Most Efficient Stocks to Buy Now
by Tirthankar Chakraborty
Companies with favorable efficiency levels are likely to be on investors' radar irrespective of market conditions.
Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals
What's in the Cards for Novartis (NVS) This Earnings Season?
by Zacks Equity Research
Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report third-quarter 2017 results on Oct 24.
Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks
by Arpita Dutt
Innovation, mergers and acquisitions (M&As), strong results, product approvals and positive data flow should act as catalysts for pharma and biotech stocks.
Will Quest Diagnostics (DGX) Disappoint in Q3 Earnings?
by Zacks Equity Research
The overall soft industry trends leading to low volume environment may continue to put a dampener on Quest Diagnostics (DGX) in Q3. The reimbursement scenario also remains a major cause for concern.
Vertex Pharmaceuticals, USG and J. Jill highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Vertex Pharmaceuticals, USG and J. Jill highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Vertex Pharmaceuticals (VRTX)
by Kevin Cook
Cystic fibrosis is a life-shortening genetic disorder affecting 75,000 youth and Vertex is leading treatment with multiple breakthroughs
Is a Beat in Store for Abbott (ABT) This Earnings Season?
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre system receives back-to-back reimbursement approvals in several geographies, which are likely to drive growth in the Diabetes Care sales segment within Medical group.
Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit
by Arpita Dutt
With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.
Amgen Label Expansion Application for Prolia Accepted by FDA
by Zacks Equity Research
Amgen (AMGN) announced that the FDA has accepted its regulatory application in the U.S. seeking label expansion for Prolia for treating patients with glucocorticoid-induced osteoporosis (GIOP).
Why the Earnings Streak Will Continue for Vertex Pharmaceuticals (VRTX)
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) is in a good position to beat earnings at its next report as it has a favorable Zacks Rank and positive Earnings ESP.
Forget Teva (TEVA), Buy These 5 Drug Stocks Instead
by Arpita Dutt
With another challenge cropping up for Teva (TEVA) in the form of earlier-than-expected generic competition for the 40 mg dose of Copaxone, here is a look at 5 drug stocks that look better-positioned.